Related Experiment Video
Updated: Jul 10, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
[Targeting ErbB receptors in breast cancer]
Pierre Fumoleau1, Mario Campone, Bruno Coudert
1Centre Georges-François Leclerc, rue du Professeur Marion, 21079 Dijon. pfumoleau@dijon.fnclcc.fr
Abstract:
Because of the involvement of the receptors of the ErbB family in breast oncogenesis, numerous approaches aimed at targeting these receptors have been developed. A monoclonal antibody directed against the ErbB2 (HER2) receptor, trastuzumab (Herceptin), has shown a high activity in palliative, neo-adjuvant and, more recently, in adjuvant setting, and has been considered as bringing a "therapeutic revolution" in breast oncology. Other antibodies, directed against ErbB2 or EGFR, are being evaluated, especially lapatinib, which should be marketed in the next future. Combinations between targeted therapies and cytotoxic chemotherapy will certainly allow to take the greatest benefits from these new treatment approaches.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
